When AML burden (as indicated by circulating cKit+ blasts) reached approximately 10% after 6 weeks, mice were randomized and treated either with miRisten or SCR control [20 mg/kg/dose/day, i.v.] for 21 days and monitored for survival (Fig. 6f). This evidence concerns the gene KIT and acute myeloid leukemia.